Finally, as recently underlined by Wong and colleagues [25], the occurrence of several activating mutations in the MAPK pathway (NRAS, BRAF, NF1, and KRAS) in mucosal melanoma and SNM open the way to select patients with tumours carrying actionable driver mutations which could be targeted using specific drug inhibitors. The gene discussed is KRAS; the disease is mucosal melanoma.